CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts

CNS Pharmaceuticals, a biotech focused on central nervous system (CNS) cancers, is advancing its lead drug candidate TPI 287 to a phase 2 clinical trial for glioblastoma multiforme, with plans to initiate the study in the first half of 202613.

The company reported a strong cash position of $12.1 million as of Q2 2025, expected to fund operations into the second half of 202613.

To bolster its finances, CNS Pharmaceuticals executed a public offering in May 2025, raising approximately $5 million by selling shares and issuing warrants to a healthcare-focused institutional investor5.

Recent biopharma sector challenges are highlighted by layoffs at multiple CNS and oncology companies, a reflection of broader financial pressures within the field2.

The proceeds of the offering will be used for working capital and general corporate purposes as the company moves towards advanced clinical development5.

Sources:

1. https://www.stocktitan.net/news/CNSP/cns-pharmaceuticals-reports-second-quarter-2025-financial-results-drl8vd9udaii.html

2. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025

3. https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-corporate-update-47151944

5. https://www.biospace.com/press-releases/cns-pharmaceuticals-announces-pricing-of-5-million-public-offering-priced-at-the-market-under-nasdaq-rules